The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...

Danish pharmaceutical giant Novo Nordisk posted a sharp rise in second-quarter net profit Wednesday, but rising competition ...

Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish ...

Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...

Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its ...

The drugmaker is a large and consistent client for Covington. The law firm has represented Novo Nordisk in several dozen ...

Furious competition in GLP-1 drugs rebuts the anti-pharma crowd.

Ozempic, the diabetes drug, induced drastic weight loss and reduced the risk of heart attacks in obese people. It became a ...

The lawsuit, which was filed in U.S. District Court in New Jersey by a single investor, Eric Barta, is a class action on ...

Novo Nordisk holds a 72% volume market share in international operations and over 50% in the US for GLP-1 receptor agonists. This market lead is based on drugs like Ozempic (semaglutide for ...

I am bullish on Novo Nordisk due to its 62% global GLP-1 market share and dominant Ozempic sales, supporting long-term leadership. Novo Nordisk's diversified GLP-1 portfolio, including Rybelsus ...